Investigation for Investors in shares of Bausch Health Companies Inc. (NYSE: BHC) announced over potential Wrongdoing by certain directors – Press Release


An investigation on behalf of investors in Bausch Health Companies Inc. (NYSE: BHC) shares over potential wrongdoing.

An investigation on behalf of investors in Bausch Health Companies Inc. (NYSE: BHC) shares over potential wrongdoing.

Certain directors of Bausch Health Companies Inc. are under investigation over potential breaches of fiduciary duties.

Investors who purchased shares of Bausch Health Companies Inc. (NYSE: BHC) have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 – 1554.

The investigation by a law firm concerns whether certain Bausch Health Companies directors breached their fiduciary duties and caused damage to the company and its shareholders.

Canada based Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. Bausch Health Companies Inc. reported that its annual Total Revenue declined from $8.6 billion in 2019 to $8.027 billion in 2020, and that its Net Loss declined from over $1.78 billion in 2019 to $560 million in 2020.

On August 3, 2021, Bausch Health Companies Inc announced its financial and operating results for the second quarter of 2021. Among other results, Bausch Health Companies Inc reported a net loss of $595 million compared to $236 million for the same period in 2020, citing an unfavorable change in operating results coupled with a decrease in the benefit from income taxes. Bausch also reported an operating loss of $270 million, compared to $27 million for the same period in 2020, which the Company stated was primarily driven by the increase in Other expense, primarily attributable to higher adjustments related to the settlement of certain litigation matters in the second quarter of 2021, an increase in Selling, general and administrative expenses and the impacts of a recall due to a quality issue at a third-party supplier partially offset by an increase in contribution due to the positive impacts of the recovery of the COVID-19 pandemic.

Shares of Bausch Health Companies Inc (NYSE: BHC) declined from $34.57 per share in March 2021 to as low as $24.91 per share on August 4, 2021.

Those who purchased shares of Bausch Health Companies Inc. (NYSE: BHC) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: [email protected]

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.